Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

475 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. Lordick F, et al. Lancet Oncol. 2013 May;14(6):490-9. doi: 10.1016/S1470-2045(13)70102-5. Epub 2013 Apr 15. Lancet Oncol. 2013. PMID: 23594786 Clinical Trial.
The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma.
Olbrich A, Niemeyer J, Seiffert H, Ebel S, Gros O, Lordick F, Forstmeyer D, Seehofer D, Rademacher S, Denecke T, Matz-Soja M, Berg T, van Bömmel F. Olbrich A, et al. Among authors: lordick f. J Cancer Res Clin Oncol. 2024 Feb 6;150(2):81. doi: 10.1007/s00432-023-05526-z. J Cancer Res Clin Oncol. 2024. PMID: 38319485 Free PMC article.
Correction: Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic.
Arndt V, Doege D, Fröhling S, Albers P, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts CH, Brossart P, Brucker SY, Brümmendorf TH, Döhner H, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, von Levetzow C, Lordick F, Neumann UP, Peters C, Schadendorf D, Stilgenbauer S, Zander T, Zips D, Braun D, Seufferlein T, Nettekoven G, Baumann M. Arndt V, et al. Among authors: lordick f. J Cancer Res Clin Oncol. 2025 Jan 18;151(1):39. doi: 10.1007/s00432-024-06060-2. J Cancer Res Clin Oncol. 2025. PMID: 39825921 Free PMC article. No abstract available.
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer.
Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, Utzolino S, Izbicki JR, Gockel I, Gerdes B, Ghadimi M, Reichert B, Lock JF, Bruns C, Reitsamer E, Schmeding M, Benedix F, Keck T, Folprecht G, Thuss-Patience P, Neumann UP, Pascher A, Imhof D, Daum S, Strieder T, Krautz C, Zimmermann S, Werner J, Mahlberg R, Illerhaus G, Grimminger P, Lordick F. Hoeppner J, et al. Among authors: lordick f. N Engl J Med. 2025 Jan 23;392(4):323-335. doi: 10.1056/NEJMoa2409408. N Engl J Med. 2025. PMID: 39842010 Clinical Trial.
Course of Mental Disorders in Early Cancer Survivorship in Relation to Socioeconomic Status: A Multi-Center Prospective Longitudinal Study (LUPE).
Springer F, Goerling U, Zimmermann T, Ernst J, Engel C, Hermann M, Esser P, Hornemann B, Keilholz U, Lordick F, Knesebeck OVD, Kissane D, Mehnert-Theuerkauf A. Springer F, et al. Among authors: lordick f. Psychooncology. 2025 Jan;34(1):e70059. doi: 10.1002/pon.70059. Psychooncology. 2025. PMID: 39780021 Free PMC article.
Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression.
Martínez-Ciarpaglini C, Barros R, Caballero C, Boggino H, Alarcón-Molero L, Peleteiro B, Ruiz-García E, Fernandez-Figueroa E, Herrera-Goepfert R, Díaz-Romero C, Ferreira R, Groen-van Schooten TS, Gauna C, Pereira R, Cantero D, Lezcano H, Esteso F, O Connor J, Riquelme A, Owen GI, Garrido M, Roa JC, Ruiz-Pace F, Vivancos A, Diez-García M, Alsina M, Matito J, Martin A, Gómez M, Castillo E, Vila M, Santos-Antunes J, Costa A, Lordick F, Farrés J, Palomar-De Lucas B, Cabeza-Segura M, Villagrasa R, Jimenez-Martí E, Miralles-Marco A, Dienstmann R, Derks S, Figueiredo C, Cervantes A, Carneiro F, Fleitas-Kanonnikoff T. Martínez-Ciarpaglini C, et al. Among authors: lordick f. Gastric Cancer. 2025 Jan 5. doi: 10.1007/s10120-024-01578-3. Online ahead of print. Gastric Cancer. 2025. PMID: 39755998
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.
Lordick F, Mauer ME, Stocker G, Cella CA, Ben-Aharon I, Piessen G, Wyrwicz L, Al-Haidari G, Fleitas-Kanonnikoff T, Boige V, Lordick Obermannová R, Martens UM, Gomez-Martin C, Thuss-Patience P, Arrazubi V, Avallone A, Shiu KK, Artru P, Brenner B, Buges Sanchez C, Chau I, Lorenzen S, Daum S, Sinn M, Merelli B, van Grieken NCT, Nilsson M, Collienne M, Giraut A, Smyth E. Lordick F, et al. Ann Oncol. 2024 Nov 13:S0923-7534(24)04906-8. doi: 10.1016/j.annonc.2024.10.829. Online ahead of print. Ann Oncol. 2024. PMID: 39542422 Free article.
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, Kang YK, Lonardi S, Hung YP, Yamaguchi K, Enzinger P, Nakajima T, Matsangou M, Cao Y, Li R, Moran D, Pophale R, Oh M, Ranganath R, Ajani JA, Xu RH. Shitara K, et al. Among authors: lordick f. N Engl J Med. 2024 Sep 26;391(12):1159-1162. doi: 10.1056/NEJMc2409512. Epub 2024 Sep 16. N Engl J Med. 2024. PMID: 39282934 No abstract available.
475 results